Oculis Holding AG (OCS) Treasury Shares (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Treasury Shares came in at -$21709.1 in Q1 2026, up 44.23% year-on-year from -$15051.3 in Q1 2025, and down 147.87% quarter-over-quarter from -$8758.2 in Q4 2025.
Oculis Holding AG (OCS) Treasury Shares (2021 - 2026) Analysis & Trends
Oculis Holding AG's Treasury Shares history runs 5 years deep, the most recent figure standing at -$21709.1 for Q1 2026.
- On a quarterly basis, Treasury Shares rose 44.23% year-over-year to -$21709.1 in Q1 2026; TTM through Mar 2026 was -$21709.1, a 44.23% increase from a year earlier, with the FY2025 full-year figure at -$8442.9, up 25.72% from the prior year.
- Treasury Shares declined to -$21709.1 in Q1 2026 per OCS's latest filing, from -$8758.2 in the prior quarter.
- Across five years, Treasury Shares topped out at -$1038.0 in Q4 2022 and bottomed at -$43753.8 in Q3 2025.
- The 4-year median for Treasury Shares is -$11542.1 (2024), against an average of -$21164.4.
- Across the five-year window, Treasury Shares tumbled 282.32% in 2025 and jumped 44.23% in 2026, its largest moves.
- Year by year, Treasury Shares stood at -$1038.0 in 2022, then sank by 999.71% to -$11415.2 in 2024, then advanced by 23.28% to -$8758.2 in 2025, then slumped by 147.87% to -$21709.1 in 2026.
- Per Business Quant, the three latest OCS Treasury Shares figures stand at -$21709.1 (Q1 2026), -$8758.2 (Q4 2025), and -$43753.8 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 265,401.92 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 34.70 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 5.14 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21,709.08 |
| Mar 31, 2026 | -21,709.08 |
| Dec 31, 2025 | -8,758.19 |
| Dec 31, 2025 | -8,758.19 |
| Sep 30, 2025 | -43,753.83 |
| Sep 30, 2025 | -43,753.83 |
| Jun 30, 2025 | -42,276.16 |
| Jun 30, 2025 | -42,276.16 |
| Mar 31, 2025 | -38,928.77 |
| Mar 31, 2025 | -38,928.77 |
| Dec 31, 2024 | -11,415.22 |
| Dec 31, 2024 | -11,415.22 |
| Sep 30, 2024 | -11,542.07 |
| Sep 30, 2024 | -11,542.07 |
| Jun 30, 2024 | -11,057.93 |
| Jun 30, 2024 | -11,057.93 |
| Dec 31, 2022 | -1,038.02 |
| Dec 31, 2022 | -1,038.02 |
| Dec 31, 2021 | 108,450.21 |
| Dec 31, 2021 | 108,450.21 |